ARCH Venture Partners today announced the closing of ARCH Venture FundXIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies.
https://mma.prnewswire.com/media/1140509/ARCH_Venture_Partners_Logo.jpg
“After more than 38 years,the ARCHinvestmentphilosophy has been consistent: webet ongreat science and great teamsto build breakthrough companies. We believe AI and new data-driven insights into biology will help to enable a more preventive, curative and equitable healthcare system. ARCH intends to continue driving the healthcare revolution,” said ARCH co-founder and Managing Director Robert Nelsen.
ARCH founds and invests in early-stage companies that prevent, detect and cure disease. Fund XIII investments to date include ArsenalBio, Metsera, Mirador Therapeutics and Xaira Therapeutics.
“ARCH is first and foremost a company builder; we foster innovation at scale to develop new technologies and medicines as rapidly as possible,” said ARCH Managing Director Kristina Burow. “We are well-positioned to continue catalyzing the next revolutions in healthcare to benefit those who matter most: patients.”
“ARCH has a long history of identifying the top forward-looking trends in life sciences R&D and the individuals driving truly breakthrough scientific hypotheses,” said ARCH co-founder and Managing Director Keith Crandell. “We remain incredibly excited by the pace of innovation and efforts to understand disease at a deeper level.”
Fund XIII follows the $2.975 billion Fund XII announced in June 2022.
ARCH’s Managing Directors include:
— Robert Nelsen
— Keith Crandell
— Kristina Burow
— Mark McDonnell
— Steve Gillis
— Paul Berns
About ARCH Venture PartnersARCH Venture Partners creates and invests in groundbreaking life science and technology companies.The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.
For more information, visitwww.archventure.com.
Contact:Morgan WarnersFGS Globalmorgan.warners@fgsglobal.com
https://c212.net/c/img/favicon.png?sn=DC16344&sd=2024-09-26
View original content to download multimedia:https://www.prnewswire.com/news-releases/arch-venture-partners-announces-new-fund-to-create-the-next-generation-of-biotech-companies-302259298.html
SOURCE ARCH Venture Partners
https://rt.newswire.ca/rt.gif?NewsItemId=DC16344&Transmission_Id=202409260800PR_NEWS_USPR_____DC16344&DateId=20240926
COMTEX_458189331/1005/2024-09-26T08:00:51